Difference between revisions of "Tumour regression"

From Libre Pathology
Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Tumour regression''' can occur as a consequence of treatment or sporadically.
'''Tumour regression''' can occur (1) sporadically, or (2) as a consequence of treatment (treatment response).


==Sporadic tumour regression==
==Sporadic tumour regression==
Line 6: Line 6:
*[[Malignant melanoma]].
*[[Malignant melanoma]].
*[[Neuroblastoma]].
*[[Neuroblastoma]].
May occur in:
*[[Basal cell carcinoma]].<ref name=Ref_Derm476>{{Ref Derm|476}}</ref>
Note:
*Melanocytic lesions in general, ''not'' only melanoma, may regress.<ref name=Ref_Derm476>{{Ref Derm|476}}</ref><ref name=pmid21029398>{{Cite journal  | last1 = Speeckaert | first1 = R. | last2 = van Geel | first2 = N. | last3 = Vermaelen | first3 = KV. | last4 = Lambert | first4 = J. | last5 = Van Gele | first5 = M. | last6 = Speeckaert | first6 = MM. | last7 = Brochez | first7 = L. | title = Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. | journal = Pigment Cell Melanoma Res | volume = 24 | issue = 2 | pages = 334-44 | month = Apr | year = 2011 | doi = 10.1111/j.1755-148X.2010.00799.x | PMID = 21029398 }}</ref>


==Microscopic==
==Microscopic==
Line 12: Line 18:
*+/-Mucin.
*+/-Mucin.
*+/-Inflammation.
*+/-Inflammation.
*+/-Histiocytes.
Note:
*There are specific criteria for ''[[malignant melanoma]]''.


===Grading of tumour regression===
===Grading of tumour regression===
There is a three tiered regression grading system by Ryan ''et al''.<ref name=pmid16045774>{{Cite journal  | last1 = Ryan | first1 = R. | last2 = Gibbons | first2 = D. | last3 = Hyland | first3 = JM. | last4 = Treanor | first4 = D. | last5 = White | first5 = A. | last6 = Mulcahy | first6 = HE. | last7 = O'Donoghue | first7 = DP. | last8 = Moriarty | first8 = M. | last9 = Fennelly | first9 = D. | title = Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. | journal = Histopathology | volume = 47 | issue = 2 | pages = 141-6 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02176.x | PMID = 16045774 }}</ref>
====Colorectal carcinoma====
{{Main|Colorectal carcinoma}}
There is a three tiered regression grading system by Ryan ''et al''. for [[colorectal cancer]].<ref name=pmid16045774>{{Cite journal  | last1 = Ryan | first1 = R. | last2 = Gibbons | first2 = D. | last3 = Hyland | first3 = JM. | last4 = Treanor | first4 = D. | last5 = White | first5 = A. | last6 = Mulcahy | first6 = HE. | last7 = O'Donoghue | first7 = DP. | last8 = Moriarty | first8 = M. | last9 = Fennelly | first9 = D. | title = Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. | journal = Histopathology | volume = 47 | issue = 2 | pages = 141-6 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02176.x | PMID = 16045774 }}</ref>
 
====Esophageal carcinoma====
*The three tier system from Ryan ''et al.'' for colorectal cancer has been applied to esophageal carcinomas.<ref>{{cite journal |authors=Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I |title=Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus |journal=Ann Surg Oncol |volume=27 |issue=4 |pages=1241–1247 |date=April 2020 |pmid=31664618 |doi=10.1245/s10434-019-07967-8 |url=}}</ref>
 
====Ovarian carcinoma====
{{Main|Ovarian carcinoma}}
This has been examined by McCluggage ''et al.''<ref name=pmid11825920>{{Cite journal  | last1 = McCluggage | first1 = WG. | last2 = Lyness | first2 = RW. | last3 = Atkinson | first3 = RJ. | last4 = Dobbs | first4 = SP. | last5 = Harley | first5 = I. | last6 = McClelland | first6 = HR. | last7 = Price | first7 = JH. | title = Morphological effects of chemotherapy on ovarian carcinoma. | journal = J Clin Pathol | volume = 55 | issue = 1 | pages = 27-31 | month = Jan | year = 2002 | doi =  | PMID = 11825920 }}</ref>


==References==
==References==

Latest revision as of 17:57, 14 March 2021

Tumour regression can occur (1) sporadically, or (2) as a consequence of treatment (treatment response).

Sporadic tumour regression

Well-known:

May occur in:

Note:

  • Melanocytic lesions in general, not only melanoma, may regress.[2][3]

Microscopic

Features:

  • +/-Fibrosis.
  • +/-Mucin.
  • +/-Inflammation.
  • +/-Histiocytes.

Note:

Grading of tumour regression

Colorectal carcinoma

There is a three tiered regression grading system by Ryan et al. for colorectal cancer.[4]

Esophageal carcinoma

  • The three tier system from Ryan et al. for colorectal cancer has been applied to esophageal carcinomas.[5]

Ovarian carcinoma

This has been examined by McCluggage et al.[6]

References

  1. Balzer, BL.; Ulbright, TM. (Jul 2006). "Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.". Am J Surg Pathol 30 (7): 858-65. doi:10.1097/01.pas.0000209831.24230.56. PMID 16819328.
  2. 2.0 2.1 Busam, Klaus J. (2009). Dermatopathology: A Volume in the Foundations in Diagnostic Pathology Series (1st ed.). Saunders. pp. 476. ISBN 978-0443066542.
  3. Speeckaert, R.; van Geel, N.; Vermaelen, KV.; Lambert, J.; Van Gele, M.; Speeckaert, MM.; Brochez, L. (Apr 2011). "Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.". Pigment Cell Melanoma Res 24 (2): 334-44. doi:10.1111/j.1755-148X.2010.00799.x. PMID 21029398.
  4. Ryan, R.; Gibbons, D.; Hyland, JM.; Treanor, D.; White, A.; Mulcahy, HE.; O'Donoghue, DP.; Moriarty, M. et al. (Aug 2005). "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.". Histopathology 47 (2): 141-6. doi:10.1111/j.1365-2559.2005.02176.x. PMID 16045774.
  5. Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I (April 2020). "Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus". Ann Surg Oncol 27 (4): 1241–1247. doi:10.1245/s10434-019-07967-8. PMID 31664618.
  6. McCluggage, WG.; Lyness, RW.; Atkinson, RJ.; Dobbs, SP.; Harley, I.; McClelland, HR.; Price, JH. (Jan 2002). "Morphological effects of chemotherapy on ovarian carcinoma.". J Clin Pathol 55 (1): 27-31. PMID 11825920.